BRCA1 and cancer: However, given the population frequency of germline BRCA1/2 PGVs, which is now being considered to be ~1 in 250 with an approximately 2:3 ratio of BRCA1/2 [63], supportive evidence for a causative association in clinical and diagnostic settings not typical of the classical HBOC cancer spectrum is important, for example through case-control studies.